The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $4.85 for the day, up 3.41% from the previous closing price of $4.69. In other words, the price has increased by $3.41 from its previous closing price. On the day, 16.76 million shares were traded. RXRX stock price reached its highest trading level at $4.87 during the session, while it also had its lowest trading level at $4.61.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.60 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.Morgan Stanley initiated its Equal-Weight rating on May 22, 2023, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’26 when Borgeson Blake sold 220,000 shares for $4.36 per share. The transaction valued at 959,200 led to the insider holds 6,649,863 shares of the business.
Gibson Christopher sold 40,000 shares of RXRX for $170,000 on Jan 05 ’26. The Director now owns 933,839 shares after completing the transaction at $4.25 per share. On Jan 06 ’26, another insider, Borgeson Blake, who serves as the Director of the company, bought 220,000 shares for $4.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2528124416 and an Enterprise Value of 1950662400. For the stock, the TTM Price-to-Sale (P/S) ratio is 57.78 while its Price-to-Book (P/B) ratio in mrq is 2.28. Its current Enterprise Value per Revenue stands at 44.649 whereas that against EBITDA is -3.058.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.96, which has changed by -0.26718748 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 8.02%, while the 200-Day Moving Average is calculated to be -3.45%.
Shares Statistics:
RXRX traded an average of 37.01M shares per day over the past three months and 19964540 shares per day over the past ten days. A total of 485.21M shares are outstanding, with a floating share count of 437.18M. Insiders hold about 15.87% of the company’s shares, while institutions hold 48.86% stake in the company. Shares short for RXRX as of 1767139200 were 165731774 with a Short Ratio of 4.48, compared to 1764288000 on 151875532. Therefore, it implies a Short% of Shares Outstanding of 165731774 and a Short% of Float of 33.73.
Earnings Estimates
The market rating for Recursion Pharmaceuticals Inc (RXRX) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.19 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.48 and -$1.7 for the fiscal current year, implying an average EPS of -$1.6. EPS for the following year is -$1.17, with 8.0 analysts recommending between -$0.63 and -$1.4.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $46.4M to a low estimate of $17.1M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $4.55MFor the next quarter, 7 analysts are estimating revenue of $16.28M. There is a high estimate of $20.2M for the next quarter, whereas the lowest estimate is $10M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $85.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $61.61M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $82.66M in the next fiscal year. The high estimate is $110.62M and the low estimate is $61.1M.
